CL
Therapeutic Areas
Newron Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Xadago® (safinamide) | Parkinson's Disease (add-on to levodopa) | Approved |
| Evenamide (NW-3509) | Treatment-Resistant Schizophrenia | Phase 3 |
| Sarizotan | Rett Syndrome (Respiratory Disturbances) | Phase 3 |
| Newron 1999 | Rare Epilepsy | Preclinical |
Leadership Team at Newron Pharmaceuticals
SW
Stefan Weber
Chief Executive Officer (CEO)
DP
Danilo Perrotti
Chief Financial Officer (CFO)
RA
Ravi Anand
Chief Medical Officer (CMO)
MC
Martino Caccia
Chief Operating Officer (COO)
LR
Lucio Rovati
Chairman of the Board of Directors
HA
Hermann A.M. Mucke
Board Member
AR
Andrea Recordati
Board Member
KA
Katherine A. High
Board Member (Scientific Advisory)
TM
Thomas Meier
Board Member